School of Biological Sciences, University of California, San Diego, La Jolla, California, United States of America.
PLoS Pathog. 2023 Apr 17;19(4):e1010943. doi: 10.1371/journal.ppat.1010943. eCollection 2023 Apr.
Influenza A virus exhibits high rates of replicative failure due to a variety of genetic defects. Most influenza virions cannot, when acting as individual particles, complete the entire viral life cycle. Nevertheless influenza is incredibly successful in the suppression of innate immune detection and the production of interferons, remaining undetected in >99% of cells in tissue-culture models of infection. Notably, the same variation that leads to replication failure can, by chance, inactivate the major innate immune antagonist in influenza A virus, NS1. What explains the observed rarity of interferon production in spite of the frequent loss of this, critical, antagonist? By studying how genetic and phenotypic variation in a viral population lacking NS1 correlates with interferon production, we have built a model of the "worst-case" failure from an improved understanding of the steps at which NS1 acts in the viral life cycle to prevent the triggering of an innate immune response. In doing so, we find that NS1 prevents the detection of de novo innate immune ligands, defective viral genomes, and viral export from the nucleus, although only generation of de novo ligands appears absolutely required for enhanced detection of virus in the absence of NS1. Due to this, the highest frequency of interferon production we observe (97% of infected cells) requires a high level of replication in the presence of defective viral genomes with NS1 bearing an inactivating mutation that does not impact its partner encoded on the same segment, NEP. This is incredibly unlikely to occur given the standard variation found within a viral population, and would generally require direct, artificial, intervention to achieve at an appreciable rate. Thus from our study, we procure at least a partial explanation for the seeming contradiction between high rates of replicative failure and the rarity of the interferon response to influenza infection.
甲型流感病毒由于多种遗传缺陷而表现出高复制失败率。大多数流感病毒粒子在作为单个颗粒时不能完成整个病毒生命周期。尽管如此,流感病毒在抑制先天免疫检测和产生干扰素方面非常成功,在组织培养感染模型中,>99%的细胞都无法检测到它。值得注意的是,导致复制失败的相同变异可能偶然使甲型流感病毒中的主要先天免疫拮抗剂 NS1 失活。尽管经常失去这种关键拮抗剂,但为什么干扰素的产生仍然如此罕见?通过研究缺乏 NS1 的病毒群体中遗传和表型变异与干扰素产生的相关性,我们通过更好地了解 NS1 在病毒生命周期中阻止先天免疫反应触发的作用步骤,构建了“最坏情况”失败模型。这样做,我们发现 NS1 阻止了新的先天免疫配体、缺陷病毒基因组以及病毒从核内输出的检测,尽管只有新的配体的产生似乎绝对需要增强没有 NS1 时对病毒的检测。因此,我们观察到的干扰素产生的最高频率(97%的感染细胞)需要在存在带有失活突变的 NS1 的缺陷病毒基因组的情况下进行高水平的复制,该突变不会影响与其在同一片段上编码的伙伴 NEP。鉴于在病毒群体中发现的标准变异,这种情况极不可能发生,通常需要直接进行人工干预才能以可观的速度实现。因此,从我们的研究中,我们至少对高复制失败率和干扰素对流感感染反应的罕见性之间的明显矛盾提供了部分解释。